Urokinase
From Proteopedia
(Difference between revisions)
| Line 21: | Line 21: | ||
**[[4dva]] – hUK catalytic domain (residues 179-431) <br /> | **[[4dva]] – hUK catalytic domain (residues 179-431) <br /> | ||
**[[4xsk]] - hUK catalytic domain (mutant) <br /> | **[[4xsk]] - hUK catalytic domain (mutant) <br /> | ||
| + | **[[5lhs]] - UK catalytic domain (mutant) - mouse<br /> | ||
*Urokinase catalytic domain complex with inhibitors | *Urokinase catalytic domain complex with inhibitors | ||
| - | **[[4fu7]], [[4fu8]], [[4fu9]], [[4fub]] - hUK + inhibitor<br /> | + | **[[4fu7]], [[4fu8]], [[4fu9]], [[4fub]], [[5xg4]] - hUK + inhibitor<br /> |
| - | **[[1fv9]] – hUK (mutant) + benzimidazole derivative | + | **[[1fv9]] – hUK (mutant) + benzimidazole derivative <br /> |
**[[4jni]], [[4jnl]] - hUK (mutant) + benzylamine derivative<br /> | **[[4jni]], [[4jnl]] - hUK (mutant) + benzylamine derivative<br /> | ||
**[[1f5k]] - hUK (mutant) + benzamidine derivative<br /> | **[[1f5k]] - hUK (mutant) + benzamidine derivative<br /> | ||
| Line 66: | Line 67: | ||
**[[4dw2]] - hUK B chain catalytic domain + antibody<br /> | **[[4dw2]] - hUK B chain catalytic domain + antibody<br /> | ||
**[[5hgg]] - hUK catalytic domain (mutant) + antibody<br /> | **[[5hgg]] - hUK catalytic domain (mutant) + antibody<br /> | ||
| + | **[[5lhn]], [[5lhr]] - mUK catalytic domain (mutant) + antibody<br /> | ||
| + | **[[5lhp]], [[5lhq]] - mUK catalytic domain (mutant) + antibody + inhibitor<br /> | ||
}} | }} | ||
==References== | ==References== | ||
Revision as of 21:44, 13 October 2017
| |||||||||||
3D Structures of urokinase
Updated on 13-October-2017
References
- ↑ Carriero MV, Stoppelli MP. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des. 2011;17(19):1944-61. PMID:21711235
- ↑ Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep. 2005 Jul;14(1):105-12. PMID:15944776
- ↑ West CW, Adler M, Arnaiz D, Chen D, Chu K, Gualtieri G, Ho E, Huwe C, Light D, Phillips G, Pulk R, Sukovich D, Whitlow M, Yuan S, Bryant J. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5712-5. Epub 2009 Aug 7. PMID:19703768 doi:10.1016/j.bmcl.2009.08.008
